Clinical value and cost analysis of the sFlt-1/PlGF ratio in addition to the spot urine protein/creatinine ratio in women with suspected pre-eclampsia: PREPARE cohort study

Table 4 Cost analysis comparing usual care to theoretical test scenarios in the first week after baseline

Health care use	Prices (€)	Usual care (€)	Scenario 1 (€) ^a	Difference 1 (€)	Scenario 2 (€)^a	Difference 2 (€)
sFlt-1/PlGF ratio test	80	–	15,920	+ 15,920	15,920	+ 15,920
Admissions ^b	71 + 590/day	52,227	45,120	− 7107	39,571	−12,656
Home monitoring ^c	109 + 108/day	4752	0	− 4752	0	−4752
Additional outpatient clinic visits/Telemonitoring ^d	168/visit 121/patient	14,279	8231	− 6047	6541	− 7738
Total per cohort	–	71,258	69,271	− 1987	62,032	− 9226
Total per patient	–	358	348	−10	312	−46

Data depicted in Euros (€)
^aScenario 1 = both tests negative (A−/−), no additional health care use in the following week; one of both tests positive (B−/+ and C+/−), one extra outpatient visit the next week and admissions conform usual care; both tests positive (D+/+), direct admission of all patients. Scenario 2: both tests negative (A−/−), no additional health care use in the following week; one of both tests positive (B−/+ and C+/−), telemonitoring during the next week and “correct” admissions conform usual care; both tests positive (D+/+), direct admission of all patients
^bMean length of stay was used for calculations. Calculations admissions usual care: 29 × 71 + 590x(7 × 1.6 + 5 × 4.4 + 8 × 3.1 + 9 × 3.0), Scenario 1: 22 × 71 + 590x(7 × 1.6 + 5 × 4.4 + 8 × 3.1 + 9 × 3.0). Scenario 2: 17 × 71 + 590x(4 × 4.5 + 4 × 5.0 + 9 × 3.0)
^cAverage number of days of home monitoring during the first week (4.5 days) was used. Calculations home monitoring usual care: 8 × 109 + 108 × 36
^dCalculations outpatient visits usual care: 168 × 85. Scenario 1: 168 × 30. Scenario 2 (telemonitoring): 121 × 54

ISSN: 1471-2393